Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tjalling Bosse

Showing results (91-100 of 167) with videos related to

Pageof 17
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 8, 2015
Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trialsTjalling Bosse, Elke E M Peters, Carien L Creutzberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2016
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC CohortsEllen Stelloo, Remi A Nout, Elisabeth M Osse, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2015
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiativeEllen Stelloo, Tjalling Bosse, Remi A Nout, et al.
Plos One|March 28, 2014
Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancersVivian M Spaans, Marjolijn D Trietsch, Stijn Crobach, et al.
Gynecologic Oncology|May 22, 2012
Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activationRemi A Nout, Tjalling Bosse, Carien L Creutzberg, et al.
Gynecologic Oncology|September 25, 2020
Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypesKim E Kortekaas, Esther Bastiaannet, Helena C van Doorn, et al.
Gynecologic Oncology|January 26, 2022
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatmentAlicia Leon-Castillo, Nanda Horeweg, Elke E M Peters, et al.
International Journal of Cancer|April 16, 2025
Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinomaVera M Witjes, Joanne A de Hullu, Dorien M A Hermkens, et al.
Cancers|October 2, 2020
The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian CarcinomasLise M van Wijk, Sylvia Vermeulen, Matty Meijers, et al.
Virchows Archiv : an International Journal of Pathology|May 13, 2022
The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significancePavel Dundr, Barbora Bazalová, Michaela Bártů, et al.
Pageof 17

Showing results (91-100 of 167) with videos related to

Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|June 8, 2015
Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trialsTjalling Bosse, Elke E M Peters, Carien L Creutzberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2016
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC CohortsEllen Stelloo, Remi A Nout, Elisabeth M Osse, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2015
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiativeEllen Stelloo, Tjalling Bosse, Remi A Nout, et al.
Plos One|March 28, 2014
Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancersVivian M Spaans, Marjolijn D Trietsch, Stijn Crobach, et al.
Gynecologic Oncology|May 22, 2012
Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activationRemi A Nout, Tjalling Bosse, Carien L Creutzberg, et al.
Gynecologic Oncology|September 25, 2020
Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypesKim E Kortekaas, Esther Bastiaannet, Helena C van Doorn, et al.
Gynecologic Oncology|January 26, 2022
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatmentAlicia Leon-Castillo, Nanda Horeweg, Elke E M Peters, et al.
International Journal of Cancer|April 16, 2025
Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinomaVera M Witjes, Joanne A de Hullu, Dorien M A Hermkens, et al.
Cancers|October 2, 2020
The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian CarcinomasLise M van Wijk, Sylvia Vermeulen, Matty Meijers, et al.
Virchows Archiv : an International Journal of Pathology|May 13, 2022
The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significancePavel Dundr, Barbora Bazalová, Michaela Bártů, et al.
Pageof 17